FDA approves use of Evusheld

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Evusheld combines monoclonal antibodies for the prevention, not treatment, of Covid-19. It is not intended to be a substitute for coronavirus vaccines.

It was developed by AstraZeneca and approved by the FDA for emergency use on June 27. It has also been authorised for emergency use by the US Food and Drug Administration and the European Union.

Evusheld is a combination of two active substances, tixagevimab co-packaged with cilgavimab, and works on the principle of "passive immunisation".

It is administered as two injections, with protection lasting for at least six months.

It can be used in adults and children from 12 years of age up weighing at least 40 kilogrammes.

Dr Paisal said people who need to use this medicine should provide doctors with information such as their history of allergies, treatment for coronary artery disease, pregnancy and vaccination history.

Do you like the content of this article?
COMMENT (6)

Thailand improves in corruption survey

Thailand has improved by nine places to 101st out of 180 countries in the 2022 Corruption Perceptions Index from 110th in 2021, Transparency International (TI) said on Tuesday.

31 Jan 2023

Anutin posters cause a stir

The Pheu Thai Party on Tuesday joined a call for the Election Commission (EC) to look into posters erected at many state-run hospitals depicting Public Health Minister Anutin Charnvirakul.

31 Jan 2023

Court lets 'Pinky' remove electronic tag

Actress Savika “Pinky” Chaiyadej on Tuesday won approval from the Criminal Court to remove an electronic monitoring (EM) device she was required to wear after her release from jail on Nov 30 last year.

31 Jan 2023